Abstract:
The fourth most prevalent cause of cancer-related deaths globally right now is gastric cancer. In the western world, it is most frequently discovered in an advanced state, after it has spread to far-off regions. Patients with advanced cancer (locally developed or metastatic), who have a poor prognosis with a median overall mortality of 10–12 months, are treated primarily with palliative chemotherapy. When compared with chemotherapy alone as first-line therapy, new methods that suppress the human epidermal growth factor receptor 2 (HER2) have demonstrated appreciable improvements in advancement-free and overall mortality in patients with HER2 overexpression. This condition has entered the age of molecular and personalized medicine with the development of medications that target vascular endothelial growth factor/vascular endothelial growth factors receptor. Immune check point inhibitors, such as anti-programmed cell death protein advancement/programmed death-ligand 1, have demonstrated tentative but positive clinical effectiveness in the management of gastric cancer. The introduction of new therapies for this condition, as well as the creation of new drugs, will heavily depend on molecular identification of patients.
Keywords: Gastric cancer, Treatment, Molecular medicine, Immunotherapy
